The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Subscribe To Our Newsletter & Stay Updated
